<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04836819</url>
  </required_header>
  <id_info>
    <org_study_id>SGPAM-DKL11</org_study_id>
    <nct_id>NCT04836819</nct_id>
  </id_info>
  <brief_title>Analgesia Management in Bariatric Surgery</brief_title>
  <official_title>Comparison of Lidocaine, Dexmedetomidine and Ketamine in Multimodal Analgesia Management Following Sleeve Gastrectomy Surgery: A Randomized Double-Blind Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ondokuz Mayıs University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ondokuz Mayıs University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Following laparoscopic bariatric surgery, multimodal analgesia is recommended to avoid the&#xD;
      adverse effects of opioids by reducing their use. Although lidocaine, ketamine, and&#xD;
      dexmedetomidine have been used as adjuvant analgesics, no studies have evaluated the&#xD;
      superiority of their intra- and postoperative infusions as components of multimodal analgesia&#xD;
      in bariatric surgery. The present study is aimed to compare lidocaine, dexmedetomidine, and&#xD;
      ketamine in multimodal analgesia management following Sleeve Gastrectomy Surgery.&#xD;
      Postoperative pain scores, the requirement for additional postoperative analgesia, retching,&#xD;
      nausea and vomiting, time to mobilization, and hospital length of stay will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be divided into three groups.&#xD;
&#xD;
      Group L: The patients will receive intravenous lidocaine (2 mg/kg/h) immediately after&#xD;
      anesthesia induction. At the end of the surgery, the dose will be decreased to 1 mg/kg/h. The&#xD;
      infusion will continue until 12 hours after the operation.&#xD;
&#xD;
      Group K: The patients will receive intravenous ketamine (0.5 mg/kg/h) immediately after&#xD;
      anesthesia induction. At the end of the surgery, the dose will be decreased to 0.3 mg/kg/h.&#xD;
      The infusion will continue until 12 hours after the operation.&#xD;
&#xD;
      Group D: The patients will receive intravenous dexmedetomidine (0.5 mg/kg/h) immediately&#xD;
      after anesthesia induction. At the end of the surgery, the dose will be decreased to 0.3&#xD;
      mg/kg/h. The infusion will continue until 12 hours after the operation.&#xD;
&#xD;
      Ketamine, lidocaine, and dexmedetomidine doses will be calculated according to ideal body&#xD;
      weight, lean body weight, and actual body weight, respectively.&#xD;
&#xD;
      Randomization will be performed using a computer-generated random number list, and a&#xD;
      statement indicating the patient's group will be placed in a closed envelope numbered&#xD;
      according to the result. Each patient will be asked to choose an envelope, and the patients&#xD;
      will be assigned to the study according to the group mentioned in the envelope.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 8, 2021</start_date>
  <completion_date type="Actual">July 1, 2021</completion_date>
  <primary_completion_date type="Actual">June 5, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The patients will be randomly classified into three groups.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Drugs to be used will be prepared 30 minutes before the surgery in the drug preparation room by a nurse who is not involved in the study. Investigators and patients will be blinded to the group assignments.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative pain: VAS scores at rest and movement</measure>
    <time_frame>Up to 15 days after the surgery.</time_frame>
    <description>Pain status at rest and movement will be assessed by VAS scores. The Visual Analog Scale (VAS) is a 10 cm line with anchor statements on the left (no pain) and on the right (worst pain imaginable).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative Rescue Analgesic Requirement</measure>
    <time_frame>Up to three days after surgery</time_frame>
    <description>After the end of surgery 25-50 mg meperidine (maximum dose 200 mg) will be administered i.m. as rescue analgesia when requested by the patient and if VAS&gt;4. the Rescue analgesic dosage will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative nausea, retching and vomiting</measure>
    <time_frame>Up to 3 days after surgery.</time_frame>
    <description>The number of patients who has complained of nausea, retching and vomiting will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first mobilization</measure>
    <time_frame>Up to 24 hours after surgery.</time_frame>
    <description>The patients first mobilization time after the operation will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to discharge</measure>
    <time_frame>Trough hospital stay, an average of 1 week.</time_frame>
    <description>The length of hospital stay will be recorded.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Morbid Obesity</condition>
  <condition>Bariatric Surgery Candidate</condition>
  <condition>Pain</condition>
  <condition>Postoperative</condition>
  <arm_group>
    <arm_group_label>Group L</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV lidocaine infusion (1-2 mg/kg/h) up to postoperative 12 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group K</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV ketamine infusion (0.3-0.5 mg/kg/h) up to postoperative 12 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV dexmedetomidine infusion (0.3-0.5 mg/kg/h) up to postoperative 12 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocain</intervention_name>
    <description>IV lidocaine infusion (2 mg/kg/h) will be initiated after anesthesia induction and decrease the dosage to 1 mg/kg/h at the end of surgery. The infusion will continue until 12 hours after the operation.1 g paracetamol, 100 mg tramadol, 100 mg ketoprofen, and 4 mg dexamethasone will be administered to all patients pre-emptively. Granisetron (3 mg) will be administered 30 minutes before the end of surgery. In the postoperative period, i.v. Paracetamol will be administered at 8-hour intervals and 25-50 mg meperidine i.m. (maximum dose 200 mg) as rescue analgesia when requested by the patient and if VAS&gt;4.</description>
    <arm_group_label>Group L</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>IV ketamine infusion (0.5 mg/kg/h) will be initiated after anesthesia induction and decrease the dosage to 0.3 mg/kg/h at the end of surgery. The infusion will continue until 12 hours after the operation.1 g paracetamol, 100 mg tramadol, 100 mg ketoprofen, and 4 mg dexamethasone will be administered to all patients pre-emptively. Granisetron (3 mg) will be administered 30 minutes before the end of surgery. In the postoperative period, i.v. Paracetamol will be administered at 8-hour intervals and 25-50 mg meperidine i.m. (maximum dose 200 mg) as rescue analgesia when requested by the patient and if VAS&gt;4.</description>
    <arm_group_label>Group K</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>IV dexmedetomidine infusion (0.5 mg/kg/h) will be initiated after anesthesia induction and decrease the dosage to 0.3 mg/kg/h at the end of surgery. The infusion will continue until 12 hours after the operation.1 g paracetamol, 100 mg tramadol, 100 mg ketoprofen, and 4 mg dexamethasone will be administered to all patients pre-emptively. Granisetron (3 mg) will be administered 30 minutes before the end of surgery. In the postoperative period, i.v. Paracetamol will be administered at 8-hour intervals and 25-50 mg meperidine i.m. (maximum dose 200 mg) as rescue analgesia when requested by the patient and if VAS&gt;4.</description>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index&gt;35 kg/m2&#xD;
&#xD;
          -  The American Society of Anaesthesiologists (ASA) physical status class II III&#xD;
&#xD;
          -  Patients who will undergo an elective laparoscopic sleeve gastrectomy (LSG)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  refusal to participate&#xD;
&#xD;
          -  allergy to the study drugs&#xD;
&#xD;
          -  chronic kidney disease (creatinine&gt;150 μmol/L)&#xD;
&#xD;
          -  mental illness&#xD;
&#xD;
          -  liver, respiratory or oncological disease,&#xD;
&#xD;
          -  cardiac dysfunction (ejection fraction &lt;40%),&#xD;
&#xD;
          -  uncontrolled hypertension,&#xD;
&#xD;
          -  preoperative analgesic use,&#xD;
&#xD;
          -  chronic pain,&#xD;
&#xD;
          -  history of alcohol or drug addiction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ersin Koksal</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ondokuz Mayıs University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ondokuz Mayis University</name>
      <address>
        <city>Samsun</city>
        <state>Atakum</state>
        <zip>55270</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Belcaid I, Eipe N. Perioperative Pain Management in Morbid Obesity. Drugs. 2019 Jul;79(11):1163-1175. doi: 10.1007/s40265-019-01156-3. Review.</citation>
    <PMID>31256367</PMID>
  </reference>
  <reference>
    <citation>Feld JM, Hoffman WE, Stechert MM, Hoffman IW, Ananda RC. Fentanyl or dexmedetomidine combined with desflurane for bariatric surgery. J Clin Anesth. 2006 Feb;18(1):24-8.</citation>
    <PMID>16517328</PMID>
  </reference>
  <reference>
    <citation>Laskowski K, Stirling A, McKay WP, Lim HJ. A systematic review of intravenous ketamine for postoperative analgesia. Can J Anaesth. 2011 Oct;58(10):911-23. doi: 10.1007/s12630-011-9560-0. Epub 2011 Jul 20. Review.</citation>
    <PMID>21773855</PMID>
  </reference>
  <reference>
    <citation>Ciftci B, Ekinci M, Celik EC, Kaciroglu A, Karakaya MA, Demiraran Y, Ozdenkaya Y. Comparison of Intravenous Ibuprofen and Paracetamol for Postoperative Pain Management after Laparoscopic Sleeve Gastrectomy. A Randomized Controlled Study. Obes Surg. 2019 Mar;29(3):765-770. doi: 10.1007/s11695-018-3613-1.</citation>
    <PMID>30474791</PMID>
  </reference>
  <reference>
    <citation>Bamgbade OA, Oluwole O, Khaw RR. Perioperative Analgesia for Fast-Track Laparoscopic Bariatric Surgery. Obes Surg. 2017 Jul;27(7):1828-1834. doi: 10.1007/s11695-017-2562-4.</citation>
    <PMID>28120147</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 5, 2021</study_first_submitted>
  <study_first_submitted_qc>April 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ondokuz Mayıs University</investigator_affiliation>
    <investigator_full_name>Yasemin Burcu Ustun</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Ketamine</keyword>
  <keyword>Lidocaine</keyword>
  <keyword>Obesity</keyword>
  <keyword>Morbid</keyword>
  <keyword>Pain</keyword>
  <keyword>Postoperative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

